Cardiac Biotech Solutions Inc Stock Price, News & Analysis

CB Scientific Inc. (OTC PINK: CBSC) has initiated an independent financial audit with MaloneBailey, LLP to assess its financial statements as of March 31, 2021. This audit is crucial for the company's objective to uplist from OTC Pink to OTCQB, requiring PCAOB compliance. The audit will provide insights into CBSC's internal controls and offer a comprehensive overview of its financial health. The process is expected to conclude within eight weeks, ensuring transparency as the company aims to keep its investors informed of any developments.

CB Scientific Inc. (OTC PINK:CBSC) has launched the Heart Wellness Check-Up program in Bangkok, Thailand, through Mango Wellness and My Cardia Thailand. This new direct-to-consumer service enables remote cardiac monitoring via 26 pharmacies and clinics. The program allows customers to monitor heart health at home for 10 days using CBSC's my-Cam™ monitor, with data transmitted to a cloud-based portal. Several major hospitals are involved, and the initiative aims to address cardiac care during the COVID-19 pandemic.

CB Scientific (OTC PINK:CBSC) announced a consultancy agreement with the Dorchester Group, led by Robert H. Hesse, to enhance its financing and marketing strategies in the U.S. and Southeast Asia. The company is expanding its Remote Cardiac Monitoring services through a distributor, Mango Wellness, collaborating with three major Thai hospitals. This initiative aims to roll out CB Scientific's my-Cam remote monitoring products. The CEO emphasized that the partnership would assist in navigating regulatory approvals, especially for its my-Cam device in mainland China.

CB Scientific, Inc. (CBSC) announced a significant partnership with three major hospital chains in Thailand to implement Remote Cardiac Monitoring Services using their my-Cam device. This agreement follows successful trials with a diagnostic success rate of 85%. The hospitals involved are Ramkhamhaeng Hospital, Bangkok Hospital Nakon Ratchasima, and Bangpakok9 Hospital. The initiative, managed through Mango Wellness Co., Ltd., aims to enhance cardiac event monitoring and improve patient outcomes. Future expansions into government hospitals are also underway.

CB Scientific (OTC PINK:CBSC) announces its acquisition of Cardiolink Corporation, a Medicare-certified Independent Diagnostic Testing Facility (IDTF) in New York, to enhance its position in the US Remote Patient Monitoring market. This strategic move aims to meet the rising demand for cardiac monitoring services, projected to grow at 18% annually from a 2019 revenue of $778M. The acquisition is expected to conclude by May 2021, aligning with CBSC's goal to address the health impacts of cardiovascular disease, which claims over 655,000 American lives yearly.

CB Scientific (CBSC) is advancing its strategic goals in the Ambulatory Remote Cardiac Monitoring market since June 2020, despite challenges posed by the COVID-19 pandemic. The company highlights key advancements, including the launch of My-Cardia ECG services in Thailand and acquisition plans for DATRIX LLC. Additionally, my-Cam device registrations in Malaysia and Singapore are set for March and April 2021, respectively. Clinical trials are ongoing with over 250,000 successful transmissions. CBSC aims for substantial growth thanks to market expansions and strategic collaborations.

CB Scientific Inc. (CBSC) has entered a collaborative partnership with Shenzhen Semacare Medical Technology to advance remote cardiac monitoring solutions. This partnership aims to leverage Semacare's MetaCor monitoring device and MetaAI technology, facilitating regulatory approvals for both companies' products in international markets. CBSC will assist Semacare in obtaining CE and FDA approvals while receiving support for its my-Cam device in China. The agreement also explores potential joint product development and future strategic business combinations.

CB Scientific (OTC: CBSC) has entered into an exclusive distribution agreement with Mango Wellness Co., Ltd. and My Cardia Thailand Co., Ltd. to launch its FDA and CE-cleared EKG products in Thailand, effective October 29, 2020.

The partnership aims to deliver advanced cardiac monitoring solutions to over 1,300 hospitals in Thailand, addressing the rising incidence of cardiovascular diseases. This move sets the stage for further expansions into Malaysia and Singapore, enhancing CBSC's footprint in the Asian market.